H. Eric Cannon, PharmD, FAMCP: Money can’t solve all our problems, but it sure helps. Can you afford your co-pays? Poverty is definitely playing into this. Homeless people [are affected]. We’re starting to work with populations that have recently been discharged from prison. There are people who don’t feel accepted. That acceptance goes across a lot of levels. If I found a physician or a therapist, but I don’t feel accepted or I don’t feel that it’s an inclusive environment, I might not keep going. That plays a role in how a patient feels. Finding ways to be more inclusive is critical for all of us.
Michael Rothrock, MBA, MHA: This is a continuing theme of our last couple of topics. We’ve [spoken] about the socioeconomic status of individuals who are the most challenging to identify and get access and care to, based on their lower income levels. At the end of the day, it comes down to education, affordability, access to care, promotion, and awareness through the workforce and your own internal HR [human resources] departments to say that there are self-help opportunities and ways to get in touch with providers or caregivers to assist you if you or a family member are experiencing symptoms of depression.
This holistic approach becomes much more magnified, and we’re much more aware as a society. We went through 2-plus years of COVID-19, and we’re trying to find the best way to [reach] these patients on a regular basis, or at least provide them the help or care they need so they can invest in themselves. As Dr Cannon mentioned, affordability is one thing. If they can’t afford the co-pays, that’s going to be a challenge. But other ways of finding care through local communities—self-help books, manufacturer-sponsored programs, church groups, even your own colleagues and friends—is something we need to see as an opportunity to [reach] these patients more frequently.
Transcript edited for clarity.
Social Determinants of Health in MDD
Key social determinants affecting MDD are evaluated by Michael Rothrock, MBA, MHA, and H. Eric Cannon, PharmD, FAMCP.
EP: 1.Unmet Needs in Treatment of MDD
EP: 2.MDD Treatment Landscape
EP: 3.Potential Consequences of Recurrent or Poorly Controlled MDD
EP: 4.Burden of Treatment Failure in MDD
EP: 5.Importance of Early Effective Treatment of MDD
EP: 6.Evaluating MDD Treatment Attributes
EP: 7.Considerations for Newly Launched MDD Treatments
EP: 8.Healthcare Disparities Within Major Depressive Disorder
EP: 9.MDD Treatment Disparities Across Patient Populations
EP: 10.Social Determinants of Health in MDD
EP: 11.Impact of COVID-19 on Demand for Mental Health Services
EP: 12.Health Care Disparities Within Major Depressive Disorder (MDD)
EP: 13.MDD Treatment Disparities Across Patient Populations: Part 2
EP: 14.Social Determinants of Health in MDD: Part 2
EP: 15.Population Health Approach in MDD
EP: 16.Factors Affecting MDD Treatment Adherence
EP: 17.Supporting Adherence for Patients with MDD
EP: 18.Aligning MDD Treatment Goals for Payers and Patients
EP: 19.The Impact of Early Effective Treatment in MDD
EP: 20.Key Contributors to Long-term Outcomes for Patients With MDD
H. Eric Cannon, PharmD, FAMCP: Money can’t solve all our problems, but it sure helps. Can you afford your co-pays? Poverty is definitely playing into this. Homeless people [are affected]. We’re starting to work with populations that have recently been discharged from prison. There are people who don’t feel accepted. That acceptance goes across a lot of levels. If I found a physician or a therapist, but I don’t feel accepted or I don’t feel that it’s an inclusive environment, I might not keep going. That plays a role in how a patient feels. Finding ways to be more inclusive is critical for all of us.
Michael Rothrock, MBA, MHA: This is a continuing theme of our last couple of topics. We’ve [spoken] about the socioeconomic status of individuals who are the most challenging to identify and get access and care to, based on their lower income levels. At the end of the day, it comes down to education, affordability, access to care, promotion, and awareness through the workforce and your own internal HR [human resources] departments to say that there are self-help opportunities and ways to get in touch with providers or caregivers to assist you if you or a family member are experiencing symptoms of depression.
This holistic approach becomes much more magnified, and we’re much more aware as a society. We went through 2-plus years of COVID-19, and we’re trying to find the best way to [reach] these patients on a regular basis, or at least provide them the help or care they need so they can invest in themselves. As Dr Cannon mentioned, affordability is one thing. If they can’t afford the co-pays, that’s going to be a challenge. But other ways of finding care through local communities—self-help books, manufacturer-sponsored programs, church groups, even your own colleagues and friends—is something we need to see as an opportunity to [reach] these patients more frequently.
Transcript edited for clarity.
AChR-Ab Titers Associated With Myasthenia Gravis Severity
February 21st 2025Anti-acetylcholine receptor antibody (AChR-Ab) titers and the AChR-Ab rates of change correlated with myasthenia gravis disease severity scores in a recent study.
Read More
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
Contributor: Beyond a One-Size-Fits-All for Managed Care Plan Benchmarks
February 20th 2025Comparing plans with similar characteristics, such as size, geographic location, or demographics served, allows for more meaningful insights and improvement opportunities.
Read More
Five Years Later: Ongoing COVID-19 Challenges, Next Steps
December 23rd 2024On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.
Listen
Ovarian Cancer Remission Rates Remained Stable Before, After COVID-19 Pandemic
February 20th 2025The comparable rates of remission pre- and post-pandemic suggest that COVID-19 did not negatively impact the outcomes of patients with ovarian cancer.
Read More
What Recent Evidence Is Telling Us About Alcohol and Cancer
February 19th 2025Evidence shows alcohol increases estrogen, raising breast cancer risk, with pandemic-related consumption spikes among women.
Read More
AChR-Ab Titers Associated With Myasthenia Gravis Severity
February 21st 2025Anti-acetylcholine receptor antibody (AChR-Ab) titers and the AChR-Ab rates of change correlated with myasthenia gravis disease severity scores in a recent study.
Read More
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
Contributor: Beyond a One-Size-Fits-All for Managed Care Plan Benchmarks
February 20th 2025Comparing plans with similar characteristics, such as size, geographic location, or demographics served, allows for more meaningful insights and improvement opportunities.
Read More
Five Years Later: Ongoing COVID-19 Challenges, Next Steps
December 23rd 2024On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.
Listen
Ovarian Cancer Remission Rates Remained Stable Before, After COVID-19 Pandemic
February 20th 2025The comparable rates of remission pre- and post-pandemic suggest that COVID-19 did not negatively impact the outcomes of patients with ovarian cancer.
Read More
What Recent Evidence Is Telling Us About Alcohol and Cancer
February 19th 2025Evidence shows alcohol increases estrogen, raising breast cancer risk, with pandemic-related consumption spikes among women.
Read More